CD8A and neoplasm: While the clinical response of GIST patients treated with imatinib is in part due to inhibition of signalling that drives tumour cell proliferation, a study performed in mouse models reported that imatinib therapy activates CD8+ T cells and induces apoptosis of Tregs [20].